Author:
Ferrari Paola,Nicolini Andrea
Reference210 articles.
1. Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: A New York cancer consortium trial. Abstract S6-03;Adelson;SABCS,2014
2. Biological reprogramming in acquired resistance to endocrine therapy of breast cancer;Aguilar;Oncogene,2010
3. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database;Anderson;Breast Cancer Research and Treatment,2002
4. Targeting FGFR with dovitinib (TKI258): Preclinical and clinical data in breast cancer;André;Clinical Cancer Research,2013
5. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients;Angus;Cancer Treatment Reviews,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献